Acasti Pharma announces that it has received notification from the NASDAQ Listing Qualifications Department that it is eligible for an additional 180 calendar days, or until July 24, 2023, to regain compliance with the minimum $1.00 per share requirement for continued listing. On July 27, 2022, Acasti received notification from NASDAQ for not maintaining a minimum bid price of US$1.00 per share for 30 consecutive business days. The Company was given 180 calendar days, or until January 23, 2023, to regain compliance.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACST:
- Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
- Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
- Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
- Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
- Acasti says preliminary results of GTX-102 study met all outcome measures
